Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.

ABSTRACT: We conducted a phase II study of the combination of temozolomide and angiogenesis inhibitors for treating adult patients with newly diagnosed glioblastoma. Patients who had stable disease following standard radiation therapy received temozolomide for 5 days in 28-day cycles, in combination with daily thalidomide and celecoxib. Patients were treated until tumor progression or development of unacceptable toxicity. Four-month progression-free survival (PFS) from study enrollment was the primary end point, and overall survival (OS) was the secondary end point. In addition, we sought to correlate response with O(6)-methylguanine-DNA methyltransferase promoter methylation status and serum levels of angiogenic peptides. Fifty patients with glioblastoma were enrolled (18 women, 32 men). Median age

SUBMITTER: Kesari S 

PROVIDER: S-EPMC2563052 | biostudies-literature | 2008 Jun

REPOSITORIES: biostudies-literature